P1NP and CTX

I ordered self-pay CTX and P1NP Bone Turnover Markers (BTM) tests through Jason Health 2 days ago. My doctor was not interested in ordering BTM tests anyway. The cost through JasonH is very reasonable for me.

$80 for the P1NP, $50 for CTX. Blood draw costs $20. Links here:
https://www.jasonhealth.com/test/16609-procollagen-type-i-intact-n-terminal-propeptide
https://www.jasonhealth.com/test/17406-collagen-type-i-c-telopeptide-ctx
I plan to have the blood draw in 4 days and post more on this forum about the whole experience when I get my results. So far it has been very good, except that the preparation instructions for one of the other tests I ordered were lacking. I rang Jason Health to ask and they emailed me links to the details of prep for each test and answered my questions.

I will also try with my PCP and/or GYN to get these tests for a more complete picture of my osteoporosis. Don’t have an ENDO yet, as they are often med/pill pushers and I need time to research and read posts here !

Per Lani Simpson - Myths and Facts:

MEMBER LEARNING POINT: If your doctors are still not ordering bone turnover markers (BTMs), copy and print the following review of all studies since 2011 and bring it to your appointment along with some chocolates along with some chocolates 🙂. The International Society of Clinical Densitometrists also recommends BTMs the same as Europe. Sad that we need to educate doctors.

Osteoporosis International. 2025 Apr;36(4):579-608.
doi: 10.1007/s00198-025-07422-3. Epub 2025 Mar 28.

Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)

Abstract
Purpose: The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) have proposed procollagen type I N propeptide (PINP) and β isomerized C-terminal telopeptide of type I collagen (β-CTX-I) as reference bone turnover markers (BTMs) for osteoporosis. This report examines the published literature since the 2011 IOF-IFCC position paper in order to determine the clinical potential of the reference BTMs and newer markers for the prediction of fracture risk and monitoring the treatment of osteoporosis.

Methods: Evidence for the relationship between BTMs and subsequent fractures was gathered from prospective studies through literature review of the Medline database from years 2011 to May 2024. The impact of treatment on BTMs was also studied by examining publications in that period. Studies of the accuracy of BTMs in the assessment of bone turnover in the setting of advanced chronic kidney disease were also examined.

Results: Increased BTM concentrations are associated with higher fracture risk in postmenopausal women. PINP and β-CTX-I measured in blood are associated with fracture risk but their interaction with other risk factors has not been sufficiently studied limiting their incorporation into fracture risk algorithms. Treatment-induced changes in PINP and β-CTX-I account for a substantial proportion of fracture risk reduction and are useful for improving adherence; they are recommended for inclusion in studies to examine adherence in individual patients. However, total PINP (tPINP) and β-CTX-I may be elevated in CKD due to renal retention. Bone alkaline phosphatase (BALP), intact PINP (iPINP), and tartrate resistant acid phosphatase 5b (TRACP5b) show the most promise in discriminating high and low turnover bone diseases in patients with advanced CKD and for predicting fracture risk, monitoring treatment response, and assessing the risk of treatment-related complications.

Conclusion: We re-affirm the use of serum/plasma tPINP and plasma β-CTX-I as reference BTMs with appropriate patient preparation and sample handling and measurement by standardized/harmonized assays in clinical studies to accumulate further data, and for monitoring treatment of osteoporosis in the setting of normal renal function in clinical practice. BALP and TRACP5b, measured by standardized assays, are recommended as reference BTMs for CKD-associated osteoporosis and should be included in observational and intervention studies to ascertain their utility for risk-evaluation, treatment initiation, and assessment of treatment response in CKD-associated osteoporosis.

Authors: Harjit Pal Bhattoa 1 , Samuel Vasikaran 2 , Ioulia Trifonidi 3 4 , Georgia Kapoula 5 , Giovanni Lombardi 6 7 , Niklas Rye Jørgensen 8 9 10 , Richard Pikner 11 12 13 , Masakazu Miura 14 , Roland Chapurlat 15 , Mickael Hiligsmann 16 , Mathias Haarhaus 17 18 , Pieter Evenepoel 19 , Hanne Skou Jørgensen 20 21 22 , Markus Herrmann 23 , Jean-Marc Kaufman 24 , Patricia Clark 25 , Şansın Tuzun 26 , Nasser Al-Daghri 27 , Stuart Silverman 28 , Majed S Alokail 27 , Sif Ormarsdóttir 29 , María Concepción Prieto Yerro 30 , Radmila Matijevic 31 , Andrea Laslop 32 , Mario Miguel Coelho da Silva Rosa 33 , Leith Zakraoui 34 , Nansa Burlet 35 , Eugene McCloskey 36 , Nicholas C Harvey 37 38 , Régis P Radermecker 39 , Maria Fusaro 40 , Carla Torre 41 42 , John A Kanis 43 , René Rizzoli 44 , Jean-Yves Reginster 27 , Konstantinos Makris 3 4 , Etienne Cavalier 45

Per Lani Simpson - Myths and Facts:

MEMBER LEARNING POINT: If your doctors are still not ordering bone turnover markers (BTMs), copy and print the following review of all studies since 2011 and bring it to your appointment along with some chocolates along with some chocolates 🙂. The International Society of Clinical Densitometrists also recommends BTMs the same as Europe. Sad that we need to educate doctors.

Osteoporosis International. 2025 Apr;36(4):579-608.
doi: 10.1007/s00198-025-07422-3. Epub 2025 Mar 28.

Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)

Abstract
Purpose: The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) have proposed procollagen type I N propeptide (PINP) and β isomerized C-terminal telopeptide of type I collagen (β-CTX-I) as reference bone turnover markers (BTMs) for osteoporosis. This report examines the published literature since the 2011 IOF-IFCC position paper in order to determine the clinical potential of the reference BTMs and newer markers for the prediction of fracture risk and monitoring the treatment of osteoporosis.

Methods: Evidence for the relationship between BTMs and subsequent fractures was gathered from prospective studies through literature review of the Medline database from years 2011 to May 2024. The impact of treatment on BTMs was also studied by examining publications in that period. Studies of the accuracy of BTMs in the assessment of bone turnover in the setting of advanced chronic kidney disease were also examined.

Results: Increased BTM concentrations are associated with higher fracture risk in postmenopausal women. PINP and β-CTX-I measured in blood are associated with fracture risk but their interaction with other risk factors has not been sufficiently studied limiting their incorporation into fracture risk algorithms. Treatment-induced changes in PINP and β-CTX-I account for a substantial proportion of fracture risk reduction and are useful for improving adherence; they are recommended for inclusion in studies to examine adherence in individual patients. However, total PINP (tPINP) and β-CTX-I may be elevated in CKD due to renal retention. Bone alkaline phosphatase (BALP), intact PINP (iPINP), and tartrate resistant acid phosphatase 5b (TRACP5b) show the most promise in discriminating high and low turnover bone diseases in patients with advanced CKD and for predicting fracture risk, monitoring treatment response, and assessing the risk of treatment-related complications.

Conclusion: We re-affirm the use of serum/plasma tPINP and plasma β-CTX-I as reference BTMs with appropriate patient preparation and sample handling and measurement by standardized/harmonized assays in clinical studies to accumulate further data, and for monitoring treatment of osteoporosis in the setting of normal renal function in clinical practice. BALP and TRACP5b, measured by standardized assays, are recommended as reference BTMs for CKD-associated osteoporosis and should be included in observational and intervention studies to ascertain their utility for risk-evaluation, treatment initiation, and assessment of treatment response in CKD-associated osteoporosis.

Authors: Harjit Pal Bhattoa 1 , Samuel Vasikaran 2 , Ioulia Trifonidi 3 4 , Georgia Kapoula 5 , Giovanni Lombardi 6 7 , Niklas Rye Jørgensen 8 9 10 , Richard Pikner 11 12 13 , Masakazu Miura 14 , Roland Chapurlat 15 , Mickael Hiligsmann 16 , Mathias Haarhaus 17 18 , Pieter Evenepoel 19 , Hanne Skou Jørgensen 20 21 22 , Markus Herrmann 23 , Jean-Marc Kaufman 24 , Patricia Clark 25 , Şansın Tuzun 26 , Nasser Al-Daghri 27 , Stuart Silverman 28 , Majed S Alokail 27 , Sif Ormarsdóttir 29 , María Concepción Prieto Yerro 30 , Radmila Matijevic 31 , Andrea Laslop 32 , Mario Miguel Coelho da Silva Rosa 33 , Leith Zakraoui 34 , Nansa Burlet 35 , Eugene McCloskey 36 , Nicholas C Harvey 37 38 , Régis P Radermecker 39 , Maria Fusaro 40 , Carla Torre 41 42 , John A Kanis 43 , René Rizzoli 44 , Jean-Yves Reginster 27 , Konstantinos Makris 3 4 , Etienne Cavalier 45

@nycmusic
Dr. McCormick does phone consultations. He will tell you which blood tests to get so he can evaluate your situation. I found most doctors are very uninformed about all the factors in buliding bone. This is too important to just go to anyone for help. Dr. McCormick prescribed my treatment (Tymlos for two years, then Evenity for one year and waiting to see what's next) and I went from -4.7 to -4.1 with Tymlos and will soon get a bone scan to see what Evenity has done for me.

@babs10 I think this proves why they are NOT. I went thru this with my docs when I started. Its all too complicated for me now, (I researched this two years ago) but my docs are happy to give me the tests but it is not as (critical) important (the P1NP and CTX) as we want to believe. Your article kinda substantiates that.